19.05

2.21% -0.43

After Hours: 18.85 -0.20 -1.05%

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $19.05, with a volume of 1.20M. It is down -2.21% in the last 24 hours and down -12.85% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Previous Close:

$19.48

Open:

$19.37

24h Volume:

1.20M

Relative Volume:

0.64

Market Cap:

$1.69B

Revenue:

$217.42M

Net Income/Loss:

$-243.25M

P/E Ratio:

-6.8153

EPS:

-2.7952

Net Cash Flow:

$-278.35M

1W Performance:

-8.46%

1M Performance:

-12.85%

6M Performance:

-6.20%

1Y Performance:

+92.04%

1-Day Range:

$18.64

$19.50

1-Week Range:

$18.64

$21.57

52-Week Range:

$9.49

$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

781-419-1400

Address

730 THIRD AVENUE, NEW YORK, MA

Employee

298

Twitter

@syndax

Next Earnings Date

2026-08-03

Latest SEC Filings

SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNDX Syndax Pharmaceuticals Inc	19.05	1.82B	217.42M	-243.25M	-278.35M	-2.7952
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-25	Resumed	H.C. Wainwright	Buy
Sep-10-25	Resumed	Stifel	Buy
Sep-04-25	Resumed	Guggenheim	Buy
Aug-05-25	Reiterated	BTIG Research	Buy
Jul-10-25	Initiated	Goldman	Buy
Oct-24-24	Initiated	UBS	Buy
Jun-28-24	Initiated	Jefferies	Buy
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

Jul 28, 2026

Syndax Pharmaceuticals to Report Second Quarter 2026 Financial Results and Host Conference Call on August 4 - Quiver Quantitative

Jul 28, 2026

Syndax will give a cancer-therapy business update Aug. 4 - Stock Titan

Jul 28, 2026

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 - GlobeNewswire

Jul 28, 2026